US20100120855A1 - Macrocylic inhibitors of hepatitis c virus - Google Patents
Macrocylic inhibitors of hepatitis c virus Download PDFInfo
- Publication number
- US20100120855A1 US20100120855A1 US11/995,941 US99594106A US2010120855A1 US 20100120855 A1 US20100120855 A1 US 20100120855A1 US 99594106 A US99594106 A US 99594106A US 2010120855 A1 US2010120855 A1 US 2010120855A1
- Authority
- US
- United States
- Prior art keywords
- formula
- alkyl
- compounds
- compound
- het
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 [1*]*C1CC2C(=O)NC3(C([2*])=O)CC3ccCOC(=O)c2c1[3*] Chemical compound [1*]*C1CC2C(=O)NC3(C([2*])=O)CC3ccCOC(=O)c2c1[3*] 0.000 description 70
- XLMJBTKWBBMJFH-XXYXIWIZSA-N COC1=CC=C2C(=C1)N=C(C1=CC=CC=C1)C=C2O[C@@H]1C[C@H]2C(=O)N[C@]3(C(=O)NS(=O)(=O)C4CC4)C[C@H]3/C=C\CCCCCOC(=O)N2C1 Chemical compound COC1=CC=C2C(=C1)N=C(C1=CC=CC=C1)C=C2O[C@@H]1C[C@H]2C(=O)N[C@]3(C(=O)NS(=O)(=O)C4CC4)C[C@H]3/C=C\CCCCCOC(=O)N2C1 XLMJBTKWBBMJFH-XXYXIWIZSA-N 0.000 description 2
- AWQPGSZGZVXQPF-WKELZURCSA-N COC1=CC=C2C(=C1)N=C(C1=CC=CC=C1)C=C2O[C@@H]1C[C@H]2C(=O)N[C@]3(C(=O)O)C[C@H]3/C=C\CCCCCOC(=O)N2C1 Chemical compound COC1=CC=C2C(=C1)N=C(C1=CC=CC=C1)C=C2O[C@@H]1C[C@H]2C(=O)N[C@]3(C(=O)O)C[C@H]3/C=C\CCCCCOC(=O)N2C1 AWQPGSZGZVXQPF-WKELZURCSA-N 0.000 description 2
- VAVOHFMYOVJHDE-UHFFFAOYSA-N COC1=CC=C2C(O)=NC(C3=CC=C(F)C=C3)=NC2=C1C Chemical compound COC1=CC=C2C(O)=NC(C3=CC=C(F)C=C3)=NC2=C1C VAVOHFMYOVJHDE-UHFFFAOYSA-N 0.000 description 2
- WCKVAWCTOGCCJG-AUHJUIHPSA-N C#CC#CC#CC([C@@H]1C[C@@]1(NC(=O)C(C)(C)C)C(=O)C(C)(C)C)=C(=C)(C)C.C#CC#CC#CC([C@H]1C[C@@]1(NC(=O)C(C)(C)C)C(=O)C(C)(C)C)=C(=C)(C)C.C=C(C)(C)=C[C@@H]1C[C@]1(NC(=O)C(C)(C)C)C(=O)C(C)(C)C.C=C(C)(C)=C[C@H]1C[C@]1(NC(=O)C(C)(C)C)C(=O)C(C)(C)C.S.S Chemical compound C#CC#CC#CC([C@@H]1C[C@@]1(NC(=O)C(C)(C)C)C(=O)C(C)(C)C)=C(=C)(C)C.C#CC#CC#CC([C@H]1C[C@@]1(NC(=O)C(C)(C)C)C(=O)C(C)(C)C)=C(=C)(C)C.C=C(C)(C)=C[C@@H]1C[C@]1(NC(=O)C(C)(C)C)C(=O)C(C)(C)C.C=C(C)(C)=C[C@H]1C[C@]1(NC(=O)C(C)(C)C)C(=O)C(C)(C)C.S.S WCKVAWCTOGCCJG-AUHJUIHPSA-N 0.000 description 1
- MLJFPAVZMLKCCE-UHFFFAOYSA-N C.CC(C)=O.[H]C(C)=O Chemical compound C.CC(C)=O.[H]C(C)=O MLJFPAVZMLKCCE-UHFFFAOYSA-N 0.000 description 1
- POOHLTQFLHKLIX-UHFFFAOYSA-N C=C(C)(C)=CC1CC1(NC(=O)C(C)(C)C)C(=O)C(C)(C)C Chemical compound C=C(C)(C)=CC1CC1(NC(=O)C(C)(C)C)C(=O)C(C)(C)C POOHLTQFLHKLIX-UHFFFAOYSA-N 0.000 description 1
- PJVAXYZPQWMXFW-UHFFFAOYSA-N C=C(C)C.CC(C)(C)OC(=O)C1CC2CC1C(=O)O2.O=C(O)C1CC2CC1C(=O)O2 Chemical compound C=C(C)C.CC(C)(C)OC(=O)C1CC2CC1C(=O)O2.O=C(O)C1CC2CC1C(=O)O2 PJVAXYZPQWMXFW-UHFFFAOYSA-N 0.000 description 1
- BHHREFADAYIPKX-YXQSPGJNSA-N C=CC1CC1(C)/N=C/C1=CC=CC=C1.C=CC1CC1(C)N.C=C[C@@H]1C[C@@]1(C)N.CC/N=C/C1=CC=CC=C1 Chemical compound C=CC1CC1(C)/N=C/C1=CC=CC=C1.C=CC1CC1(C)N.C=C[C@@H]1C[C@@]1(C)N.CC/N=C/C1=CC=CC=C1 BHHREFADAYIPKX-YXQSPGJNSA-N 0.000 description 1
- LCOZBCNZLBRFPU-UHFFFAOYSA-N C=CCCCCO.C=CCCCCOC(=O)OC1=CC=C([N+](=O)[O-])C=C1.O=C(Cl)OC1=CC=C([N+](=O)[O-])C=C1 Chemical compound C=CCCCCO.C=CCCCCOC(=O)OC1=CC=C([N+](=O)[O-])C=C1.O=C(Cl)OC1=CC=C([N+](=O)[O-])C=C1 LCOZBCNZLBRFPU-UHFFFAOYSA-N 0.000 description 1
- UAWLPBOQJQKFEO-UHFFFAOYSA-N C=CCCCCO.C=CCCCCOC(=O)ON1C(=O)CCC1=O.O=C(ON1C(=O)CCC1=O)ON1C(=O)CCC1=O Chemical compound C=CCCCCO.C=CCCCCOC(=O)ON1C(=O)CCC1=O.O=C(ON1C(=O)CCC1=O)ON1C(=O)CCC1=O UAWLPBOQJQKFEO-UHFFFAOYSA-N 0.000 description 1
- GWZGTFTUIRQJBP-ZDZVLFQESA-N C=CCCCCOC(=O)N1C[C@H](OC2=CC(C3=CC=CC=C3)=NC3=CC(OC)=CC=C32)C[C@H]1C(=O)N[C@]1(C(=O)OCC)C[C@H]1C=C.C=CCCCCOC(=O)OC1=CC=C([N+](=O)[O-])C=C1.C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](OC2=CC(C3=CC=CC=C3)=NC3=CC(OC)=CC=C32)CN1C(=O)OC(C)(C)C)C(=O)OCC Chemical compound C=CCCCCOC(=O)N1C[C@H](OC2=CC(C3=CC=CC=C3)=NC3=CC(OC)=CC=C32)C[C@H]1C(=O)N[C@]1(C(=O)OCC)C[C@H]1C=C.C=CCCCCOC(=O)OC1=CC=C([N+](=O)[O-])C=C1.C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](OC2=CC(C3=CC=CC=C3)=NC3=CC(OC)=CC=C32)CN1C(=O)OC(C)(C)C)C(=O)OCC GWZGTFTUIRQJBP-ZDZVLFQESA-N 0.000 description 1
- BNBTXFWVIMVMLQ-IFOGYPIUSA-N C=CCCCCOC(=O)N1C[C@H](OC2=CC(C3=CC=CC=C3)=NC3=CC(OC)=CC=C32)C[C@H]1C(=O)N[C@]1(C(=O)OCC)C[C@H]1C=C.CCOC(=O)[C@@]12C[C@H]1/C=C\CCCCOC(=O)N1C[C@H](OC3=CC(C4=CC=CC=C4)=NC4=CC(OC)=CC=C43)C[C@H]1C(=O)N2 Chemical compound C=CCCCCOC(=O)N1C[C@H](OC2=CC(C3=CC=CC=C3)=NC3=CC(OC)=CC=C32)C[C@H]1C(=O)N[C@]1(C(=O)OCC)C[C@H]1C=C.CCOC(=O)[C@@]12C[C@H]1/C=C\CCCCOC(=O)N1C[C@H](OC3=CC(C4=CC=CC=C4)=NC4=CC(OC)=CC=C43)C[C@H]1C(=O)N2 BNBTXFWVIMVMLQ-IFOGYPIUSA-N 0.000 description 1
- HCFTXYBOTNLRRM-SNIHSBJDSA-N C=CCCCCOC(=O)N1C[C@H](OC2=NC(Cl)=CC3=C2C=CC(OC)=C3)C[C@H]1C(=O)N[C@]1(C(=O)OCC)C[C@H]1C=C.C=CCCCCOC(=O)ON1C(=O)CCC1=O.C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](OC2=NC(Cl)=CC3=C2C=CC(OC)=C3)CN1)C(=O)OCC Chemical compound C=CCCCCOC(=O)N1C[C@H](OC2=NC(Cl)=CC3=C2C=CC(OC)=C3)C[C@H]1C(=O)N[C@]1(C(=O)OCC)C[C@H]1C=C.C=CCCCCOC(=O)ON1C(=O)CCC1=O.C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](OC2=NC(Cl)=CC3=C2C=CC(OC)=C3)CN1)C(=O)OCC HCFTXYBOTNLRRM-SNIHSBJDSA-N 0.000 description 1
- RWSFTVYVUPLWGC-BKIYIIEWSA-N C=CCCCCOC(=O)N1C[C@H](OC2=NC(Cl)=CC3=C2C=CC(OC)=C3)C[C@H]1C(=O)N[C@]1(C(=O)OCC)C[C@H]1C=C.CCOC(=O)[C@@]12C[C@H]1/C=C\CCCCOC(=O)N1C[C@H](OC3=NC(Cl)=CC4=CC(OC)=CC=C43)C[C@H]1C(=O)N2 Chemical compound C=CCCCCOC(=O)N1C[C@H](OC2=NC(Cl)=CC3=C2C=CC(OC)=C3)C[C@H]1C(=O)N[C@]1(C(=O)OCC)C[C@H]1C=C.CCOC(=O)[C@@]12C[C@H]1/C=C\CCCCOC(=O)N1C[C@H](OC3=NC(Cl)=CC4=CC(OC)=CC=C43)C[C@H]1C(=O)N2 RWSFTVYVUPLWGC-BKIYIIEWSA-N 0.000 description 1
- CCHMDQSFUJGRLH-UHFFFAOYSA-N C=CCO.C=CCOC(C)=O.CC(C)=O Chemical compound C=CCO.C=CCOC(C)=O.CC(C)=O CCHMDQSFUJGRLH-UHFFFAOYSA-N 0.000 description 1
- FALZWBRSKQXANJ-UHFFFAOYSA-N C=CCO.CC(=O)Cl Chemical compound C=CCO.CC(=O)Cl FALZWBRSKQXANJ-UHFFFAOYSA-N 0.000 description 1
- XRFWKHVQMACVTA-UHFFFAOYSA-N C=CCOC(=O)CC Chemical compound C=CCOC(=O)CC XRFWKHVQMACVTA-UHFFFAOYSA-N 0.000 description 1
- NHFOSEDYYBABGE-UHFFFAOYSA-N C=CCOC(=O)[W] Chemical compound C=CCOC(=O)[W] NHFOSEDYYBABGE-UHFFFAOYSA-N 0.000 description 1
- LOZLYXCPYHPMBN-HIMNDZMNSA-N C=C[C@@H]1C[C@]1(N)C(=O)OCC.C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](OC2=C3C=CC(OC)=CC3=NC(C3=CC=CC=C3)=C2)CN1C(=O)OC(C)(C)C)C(=O)OCC.COC1=CC2=NC(C3=CC=CC=C3)=CC(O[C@@H]3C[C@@H](C(=O)O)N(C(=O)OC(C)(C)C)C3)=C2C=C1 Chemical compound C=C[C@@H]1C[C@]1(N)C(=O)OCC.C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](OC2=C3C=CC(OC)=CC3=NC(C3=CC=CC=C3)=C2)CN1C(=O)OC(C)(C)C)C(=O)OCC.COC1=CC2=NC(C3=CC=CC=C3)=CC(O[C@@H]3C[C@@H](C(=O)O)N(C(=O)OC(C)(C)C)C3)=C2C=C1 LOZLYXCPYHPMBN-HIMNDZMNSA-N 0.000 description 1
- MHMGCXAHBMOWRK-LYRILTQVSA-N C=C[C@@H]1C[C@]1(N)C(=O)OCC.C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](OC2=NC(Cl)=CC3=C2C=CC(OC)=C3)CN1C(=O)OC(C)(C)C)C(=O)OCC.COC1=CC2=C(C=C1)C(O[C@@H]1C[C@@H](C(=O)O)N(C(=O)OC(C)(C)C)C1)=NC(Cl)=C2.Cl Chemical compound C=C[C@@H]1C[C@]1(N)C(=O)OCC.C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](OC2=NC(Cl)=CC3=C2C=CC(OC)=C3)CN1C(=O)OC(C)(C)C)C(=O)OCC.COC1=CC2=C(C=C1)C(O[C@@H]1C[C@@H](C(=O)O)N(C(=O)OC(C)(C)C)C1)=NC(Cl)=C2.Cl MHMGCXAHBMOWRK-LYRILTQVSA-N 0.000 description 1
- IKNUHYRTIHKIJH-HBQADSCCSA-N C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](OC2=NC(Cl)=CC3=C2C=CC(OC)=C3)CN1)C(=O)OCC.C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](OC2=NC(Cl)=CC3=C2C=CC(OC)=C3)CN1C(=O)OC(C)(C)C)C(=O)OCC Chemical compound C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](OC2=NC(Cl)=CC3=C2C=CC(OC)=C3)CN1)C(=O)OCC.C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](OC2=NC(Cl)=CC3=C2C=CC(OC)=C3)CN1C(=O)OC(C)(C)C)C(=O)OCC IKNUHYRTIHKIJH-HBQADSCCSA-N 0.000 description 1
- SGWRZXZIMCNSNY-UHFFFAOYSA-N CC(=O)C1CC2CC1C(=O)O2 Chemical compound CC(=O)C1CC2CC1C(=O)O2 SGWRZXZIMCNSNY-UHFFFAOYSA-N 0.000 description 1
- DQUFSAODILCLEH-UHFFFAOYSA-N CC(C)(C)N1CC2=C(C=CC=C2)C1.CC(C)(C)N1CCC2=C(C=CC=C2)C1.CC(C)(C)N1CCC2=C1C=CC=C2.CC(C)(C)N1CCCC2=C1C=CC=C2.CC(C)(C)N1CCOC2=C1C=CC=C2 Chemical compound CC(C)(C)N1CC2=C(C=CC=C2)C1.CC(C)(C)N1CCC2=C(C=CC=C2)C1.CC(C)(C)N1CCC2=C1C=CC=C2.CC(C)(C)N1CCCC2=C1C=CC=C2.CC(C)(C)N1CCOC2=C1C=CC=C2 DQUFSAODILCLEH-UHFFFAOYSA-N 0.000 description 1
- CEODIHZZMDLFHC-UHFFFAOYSA-N CC(C)(C)OC(=O)C1CC2CC1C(=O)O2 Chemical compound CC(C)(C)OC(=O)C1CC2CC1C(=O)O2 CEODIHZZMDLFHC-UHFFFAOYSA-N 0.000 description 1
- VDMQZOQONDMOOO-VVOLSGPISA-N CC(C)(C)OC(=O)N1C[C@H](O)C[C@H]1C(=O)O.COC1=CC2=C(C=C1)C(Cl)=NC(Cl)=C2.COC1=CC2=C(C=C1)C(O[C@@H]1C[C@@H](C(=O)O)N(C(=O)OC(C)(C)C)C1)=NC(Cl)=C2 Chemical compound CC(C)(C)OC(=O)N1C[C@H](O)C[C@H]1C(=O)O.COC1=CC2=C(C=C1)C(Cl)=NC(Cl)=C2.COC1=CC2=C(C=C1)C(O[C@@H]1C[C@@H](C(=O)O)N(C(=O)OC(C)(C)C)C1)=NC(Cl)=C2 VDMQZOQONDMOOO-VVOLSGPISA-N 0.000 description 1
- RPJLBTAVBSFSMR-TWPQILIZSA-N CC(C)(C)OC(=O)N1C[C@H](O)C[C@H]1C(=O)O.COC1=CC2=NC(C3=CC=CC=C3)=CC(Cl)=C2C=C1.COC1=CC2=NC(C3=CC=CC=C3)=CC(O[C@@H]3C[C@@H](C(=O)O)N(C(=O)OC(C)(C)C)C3)=C2C=C1 Chemical compound CC(C)(C)OC(=O)N1C[C@H](O)C[C@H]1C(=O)O.COC1=CC2=NC(C3=CC=CC=C3)=CC(Cl)=C2C=C1.COC1=CC2=NC(C3=CC=CC=C3)=CC(O[C@@H]3C[C@@H](C(=O)O)N(C(=O)OC(C)(C)C)C3)=C2C=C1 RPJLBTAVBSFSMR-TWPQILIZSA-N 0.000 description 1
- HPOGWYOOLVLEIB-UHFFFAOYSA-N CC(C)=O.CCO.[H]C(C)=O Chemical compound CC(C)=O.CCO.[H]C(C)=O HPOGWYOOLVLEIB-UHFFFAOYSA-N 0.000 description 1
- OIUMISWUCQBVMY-UHFFFAOYSA-N CC(C)C1=CSC(C(C)C)=N1.CC(C)C1=NC(C(C)(C)C)=CS1.CC1=C(C)SC(C(C)C)=N1.CC1=CN=C(C(C)C)S1.CC1=CSC(C(C)C)=N1.CCC1=CN=C(C(C)C)S1.CCC1=CSC(C(C)C)=N1 Chemical compound CC(C)C1=CSC(C(C)C)=N1.CC(C)C1=NC(C(C)(C)C)=CS1.CC1=C(C)SC(C(C)C)=N1.CC1=CN=C(C(C)C)S1.CC1=CSC(C(C)C)=N1.CCC1=CN=C(C(C)C)S1.CCC1=CSC(C(C)C)=N1 OIUMISWUCQBVMY-UHFFFAOYSA-N 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N CC(C)C1=NC(CN(C)C(=O)N[C@H](C(=O)N[C@@H](CC2=CC=CC=C2)C[C@H](O)[C@H](CC2=CC=CC=C2)NC(=O)OCC2=CN=CS2)C(C)C)=CS1 Chemical compound CC(C)C1=NC(CN(C)C(=O)N[C@H](C(=O)N[C@@H](CC2=CC=CC=C2)C[C@H](O)[C@H](CC2=CC=CC=C2)NC(=O)OCC2=CN=CS2)C(C)C)=CS1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- FZOPOGOWKANCHS-UHFFFAOYSA-N CCC1=NC2=C(C)C(OC)=CC=C2C(O)=N1 Chemical compound CCC1=NC2=C(C)C(OC)=CC=C2C(O)=N1 FZOPOGOWKANCHS-UHFFFAOYSA-N 0.000 description 1
- NOCHUYZVPKEJGE-UHFFFAOYSA-N CCOC(=O)C1=C(O)C=C(N)C(C#N)=C1.COC1=CC=C(C#N)C(N)=C1.COC1=CC=C(C(C)=O)C(N)=C1.N#CC1=CC(C(=O)O)=C(O)C=C1N.N#CC1=CC=C(O)C=C1N Chemical compound CCOC(=O)C1=C(O)C=C(N)C(C#N)=C1.COC1=CC=C(C#N)C(N)=C1.COC1=CC=C(C(C)=O)C(N)=C1.N#CC1=CC(C(=O)O)=C(O)C=C1N.N#CC1=CC=C(O)C=C1N NOCHUYZVPKEJGE-UHFFFAOYSA-N 0.000 description 1
- OWBRTIVGENWDIM-LJWFRKTASA-N CCOC(=O)[C@@]12C[C@H]1/C=C\CCCCOC(=O)N1C[C@H](OC3=CC(C4=CC=CC=C4)=NC4=CC(OC)=CC=C43)C[C@H]1C(=O)N2.COC1=CC=C2C(=C1)N=C(C1=CC=CC=C1)C=C2O[C@@H]1C[C@H]2C(=O)N[C@]3(C(=O)O)C[C@H]3/C=C\CCCCOC(=O)N2C1 Chemical compound CCOC(=O)[C@@]12C[C@H]1/C=C\CCCCOC(=O)N1C[C@H](OC3=CC(C4=CC=CC=C4)=NC4=CC(OC)=CC=C43)C[C@H]1C(=O)N2.COC1=CC=C2C(=C1)N=C(C1=CC=CC=C1)C=C2O[C@@H]1C[C@H]2C(=O)N[C@]3(C(=O)O)C[C@H]3/C=C\CCCCOC(=O)N2C1 OWBRTIVGENWDIM-LJWFRKTASA-N 0.000 description 1
- LQOLOIRVSURBLZ-RQFOSTCYSA-N CCOC(=O)[C@@]12C[C@H]1/C=C\CCCCOC(=O)N1C[C@H](OC3=NC(Cl)=CC4=CC(OC)=CC=C43)C[C@H]1C(=O)N2.COC1=CC=C2C(=C1)C=C(Cl)N=C2O[C@@H]1C[C@H]2C(=O)N[C@]3(C(=O)O)C[C@H]3/C=C\CCCCOC(=O)N2C1 Chemical compound CCOC(=O)[C@@]12C[C@H]1/C=C\CCCCOC(=O)N1C[C@H](OC3=NC(Cl)=CC4=CC(OC)=CC=C43)C[C@H]1C(=O)N2.COC1=CC=C2C(=C1)C=C(Cl)N=C2O[C@@H]1C[C@H]2C(=O)N[C@]3(C(=O)O)C[C@H]3/C=C\CCCCOC(=O)N2C1 LQOLOIRVSURBLZ-RQFOSTCYSA-N 0.000 description 1
- FEXBSQIEYCLONS-HBZJJEJRSA-N CCOC([C@@](C1)([C@@H]1/C=C\CCCCOC(N(C1)[C@H]2C[C@H]1Oc1c(ccc(OC)c3)c3cc(Cl)n1)=O)NC2=O)=O Chemical compound CCOC([C@@](C1)([C@@H]1/C=C\CCCCOC(N(C1)[C@H]2C[C@H]1Oc1c(ccc(OC)c3)c3cc(Cl)n1)=O)NC2=O)=O FEXBSQIEYCLONS-HBZJJEJRSA-N 0.000 description 1
- MLPVBIWIRCKMJV-UHFFFAOYSA-N CCc1ccccc1N Chemical compound CCc1ccccc1N MLPVBIWIRCKMJV-UHFFFAOYSA-N 0.000 description 1
- WBJWDZRASFPPDG-UHFFFAOYSA-N COC(=O)C1=CC(O)CC1C(=O)O.COC(=O)C1=CC(O)CC1C(=O)OC.COC(=O)C1CC(=O)CC1C(=O)OC Chemical compound COC(=O)C1=CC(O)CC1C(=O)O.COC(=O)C1=CC(O)CC1C(=O)OC.COC(=O)C1CC(=O)CC1C(=O)OC WBJWDZRASFPPDG-UHFFFAOYSA-N 0.000 description 1
- ABNCNERHBZBYRH-UHFFFAOYSA-N COC(=O)C1=CC=C(OC)C(C)=C1NC(=O)C1=CC=C(F)C=C1 Chemical compound COC(=O)C1=CC=C(OC)C(C)=C1NC(=O)C1=CC=C(F)C=C1 ABNCNERHBZBYRH-UHFFFAOYSA-N 0.000 description 1
- NWXBVPNHAHFNDG-ARFSIUBOSA-N COC1=CC2=C(C=C1)C(O[C@@H]1C[C@H]3C(=O)N[C@]4(C(=O)NS(=O)(=O)C5CC5)C[C@H]4/C=C\CCCCOC(=O)N3C1)=CC(C1=CC=CC=C1)=N2 Chemical compound COC1=CC2=C(C=C1)C(O[C@@H]1C[C@H]3C(=O)N[C@]4(C(=O)NS(=O)(=O)C5CC5)C[C@H]4/C=C\CCCCOC(=O)N3C1)=CC(C1=CC=CC=C1)=N2 NWXBVPNHAHFNDG-ARFSIUBOSA-N 0.000 description 1
- VJOZYSDLFSYCPI-UHFFFAOYSA-N COC1=CC=C(C(=O)O)C(NC(=O)C2=CC=C(F)C=C2)=C1C Chemical compound COC1=CC=C(C(=O)O)C(NC(=O)C2=CC=C(F)C=C2)=C1C VJOZYSDLFSYCPI-UHFFFAOYSA-N 0.000 description 1
- OXPHEYWQCYFJMF-UHFFFAOYSA-N COC1=CC=C(C2=NC3=C(C)C(OC)=CC=C3C(O)=N2)C=C1 Chemical compound COC1=CC=C(C2=NC3=C(C)C(OC)=CC=C3C(O)=N2)C=C1 OXPHEYWQCYFJMF-UHFFFAOYSA-N 0.000 description 1
- OLECIWDDIUMMSV-UHFFFAOYSA-N COC1=CC=C2C(=C1)C(Br)=CN=C2O.COC1=CC=C2C(=C1)C=CN=C2O Chemical compound COC1=CC=C2C(=C1)C(Br)=CN=C2O.COC1=CC=C2C(=C1)C=CN=C2O OLECIWDDIUMMSV-UHFFFAOYSA-N 0.000 description 1
- NMCHLMUNVWLIIA-UHFFFAOYSA-N COC1=CC=C2C(=C1)C=C(Cl)N=C2Cl.COC1=CC=C2C(=C1)C=C[N+]([O-])=C2Cl Chemical compound COC1=CC=C2C(=C1)C=C(Cl)N=C2Cl.COC1=CC=C2C(=C1)C=C[N+]([O-])=C2Cl NMCHLMUNVWLIIA-UHFFFAOYSA-N 0.000 description 1
- XQNSGMJILVCEJU-RAEMPFAGSA-N COC1=CC=C2C(=C1)C=C(Cl)N=C2OC1C[C@H]2C(=O)N[C@]3(C(=O)O)CC3/C=C\CCCCOC(=O)N2C1 Chemical compound COC1=CC=C2C(=C1)C=C(Cl)N=C2OC1C[C@H]2C(=O)N[C@]3(C(=O)O)CC3/C=C\CCCCOC(=O)N2C1 XQNSGMJILVCEJU-RAEMPFAGSA-N 0.000 description 1
- KMRSRQTYTCFVAX-LTYXBVNVSA-N COC1=CC=C2C(=C1)C=C(Cl)N=C2O[C@@H]1C[C@H]2C(=O)N[C@]3(C(=O)NS(=O)(=O)C4CC4)C[C@H]3/C=C\CCCCOC(=O)N2C1 Chemical compound COC1=CC=C2C(=C1)C=C(Cl)N=C2O[C@@H]1C[C@H]2C(=O)N[C@]3(C(=O)NS(=O)(=O)C4CC4)C[C@H]3/C=C\CCCCOC(=O)N2C1 KMRSRQTYTCFVAX-LTYXBVNVSA-N 0.000 description 1
- FWWNTYWJHNDMNA-OKQKCPIASA-N COC1=CC=C2C(=C1)C=C(Cl)N=C2O[C@@H]1C[C@H]2C(=O)N[C@]3(C(=O)NS(=O)(=O)C4CC4)C[C@H]3/C=C\CCCCOC(=O)N2C1.COC1=CC=C2C(=C1)C=C(Cl)N=C2O[C@@H]1C[C@H]2C(=O)N[C@]3(C(=O)O)C[C@H]3/C=C\CCCCOC(=O)N2C1 Chemical compound COC1=CC=C2C(=C1)C=C(Cl)N=C2O[C@@H]1C[C@H]2C(=O)N[C@]3(C(=O)NS(=O)(=O)C4CC4)C[C@H]3/C=C\CCCCOC(=O)N2C1.COC1=CC=C2C(=C1)C=C(Cl)N=C2O[C@@H]1C[C@H]2C(=O)N[C@]3(C(=O)O)C[C@H]3/C=C\CCCCOC(=O)N2C1 FWWNTYWJHNDMNA-OKQKCPIASA-N 0.000 description 1
- IYQYFXWKQCWMLF-UHFFFAOYSA-N COC1=CC=C2C(=C1)C=CN=C2Cl.COC1=CC=C2C(=C1)C=CN=C2O Chemical compound COC1=CC=C2C(=C1)C=CN=C2Cl.COC1=CC=C2C(=C1)C=CN=C2O IYQYFXWKQCWMLF-UHFFFAOYSA-N 0.000 description 1
- CSUAPCFVUJTJAV-UHFFFAOYSA-N COC1=CC=C2C(=C1)C=CN=C2Cl.COC1=CC=C2C(=C1)C=C[N+]([O-])=C2Cl Chemical compound COC1=CC=C2C(=C1)C=CN=C2Cl.COC1=CC=C2C(=C1)C=C[N+]([O-])=C2Cl CSUAPCFVUJTJAV-UHFFFAOYSA-N 0.000 description 1
- BYKIBYUEALCXIF-LSOVHFRFSA-N COC1=CC=C2C(=C1)N=C(C1=CC=CC=C1)C=C2O[C@@H]1C[C@H]2C(=O)N[C@]3(C(=O)NS(=O)(=O)C4CC4)C[C@H]3/C=C\CCCCOC(=O)N2C1.COC1=CC=C2C(=C1)N=C(C1=CC=CC=C1)C=C2O[C@@H]1C[C@H]2C(=O)N[C@]3(C(=O)O)C[C@H]3/C=C\CCCCOC(=O)N2C1 Chemical compound COC1=CC=C2C(=C1)N=C(C1=CC=CC=C1)C=C2O[C@@H]1C[C@H]2C(=O)N[C@]3(C(=O)NS(=O)(=O)C4CC4)C[C@H]3/C=C\CCCCOC(=O)N2C1.COC1=CC=C2C(=C1)N=C(C1=CC=CC=C1)C=C2O[C@@H]1C[C@H]2C(=O)N[C@]3(C(=O)O)C[C@H]3/C=C\CCCCOC(=O)N2C1 BYKIBYUEALCXIF-LSOVHFRFSA-N 0.000 description 1
- ZNKKFPUPLGASNG-XCTNLMGJSA-N COC1=CC=C2C(=C1)N=C(C1=CC=CC=C1)C=C2O[C@@H]1C[C@H]2C(=O)N[C@]3(C(=O)O)CC3/C=C\CCCCOC(=O)N2C1 Chemical compound COC1=CC=C2C(=C1)N=C(C1=CC=CC=C1)C=C2O[C@@H]1C[C@H]2C(=O)N[C@]3(C(=O)O)CC3/C=C\CCCCOC(=O)N2C1 ZNKKFPUPLGASNG-XCTNLMGJSA-N 0.000 description 1
- OMNSOCCTBRGFJF-MXDQRGINSA-N COC1=CC=C2C(O)=CC=CC2=C1.COC1=CC=CC(/C=C/C(=O)N=[N+]=[N-])=C1 Chemical compound COC1=CC=C2C(O)=CC=CC2=C1.COC1=CC=CC(/C=C/C(=O)N=[N+]=[N-])=C1 OMNSOCCTBRGFJF-MXDQRGINSA-N 0.000 description 1
- MPMZRDZHKGBHGD-UHFFFAOYSA-N COC1=CC=C2C(O)=NC(C3=CC(F)=CC(F)=C3)=NC2=C1C Chemical compound COC1=CC=C2C(O)=NC(C3=CC(F)=CC(F)=C3)=NC2=C1C MPMZRDZHKGBHGD-UHFFFAOYSA-N 0.000 description 1
- AJJLQHVGZQTMRE-UHFFFAOYSA-N COC1=CC=C2C(O)=NC(C3=CC(F)=CC=C3)=NC2=C1C Chemical compound COC1=CC=C2C(O)=NC(C3=CC(F)=CC=C3)=NC2=C1C AJJLQHVGZQTMRE-UHFFFAOYSA-N 0.000 description 1
- QRCGGGQGCLVNFF-UHFFFAOYSA-N COC1=CC=C2C(O)=NC(C3=CC=CC=C3)=NC2=C1C Chemical compound COC1=CC=C2C(O)=NC(C3=CC=CC=C3)=NC2=C1C QRCGGGQGCLVNFF-UHFFFAOYSA-N 0.000 description 1
- UTGFUAQJGQSIIY-UHFFFAOYSA-N COC1=CC=C2C(O)=NC(C3=CC=NC=C3)=NC2=C1C Chemical compound COC1=CC=C2C(O)=NC(C3=CC=NC=C3)=NC2=C1C UTGFUAQJGQSIIY-UHFFFAOYSA-N 0.000 description 1
- LUAIMRWRJPHQET-UHFFFAOYSA-N COC1=CC=C2C(O)=NC(C3=CN=CC=C3)=NC2=C1C Chemical compound COC1=CC=C2C(O)=NC(C3=CN=CC=C3)=NC2=C1C LUAIMRWRJPHQET-UHFFFAOYSA-N 0.000 description 1
- PGRJUTLFMUYRKN-UHFFFAOYSA-N COC1=CC=C2C(O)=NC=NC2=C1C Chemical compound COC1=CC=C2C(O)=NC=NC2=C1C PGRJUTLFMUYRKN-UHFFFAOYSA-N 0.000 description 1
- CHALVHUQKVYUHV-HBVWGTQWSA-N COC1=CC=CC(/C=C/C(=O)N=[N+]=[N-])=C1.COC1=CC=CC(/C=C/C(=O)O)=C1 Chemical compound COC1=CC=CC(/C=C/C(=O)N=[N+]=[N-])=C1.COC1=CC=CC(/C=C/C(=O)O)=C1 CHALVHUQKVYUHV-HBVWGTQWSA-N 0.000 description 1
- NBWQDCBSEDCJIQ-YYZFZGLGSA-N COc(cc1)cc2c1c(O[C@H](C[C@H]1C(N[C@](C3)([C@@H]3CCCCCCO3)C(O)=O)=O)CN1C3=O)nc(Cl)c2 Chemical compound COc(cc1)cc2c1c(O[C@H](C[C@H]1C(N[C@](C3)([C@@H]3CCCCCCO3)C(O)=O)=O)CN1C3=O)nc(Cl)c2 NBWQDCBSEDCJIQ-YYZFZGLGSA-N 0.000 description 1
- YZUIVMCMLUKIBS-VOTSOKGWSA-N COc1cccc(/C=C/C(N=C)=O)c1 Chemical compound COc1cccc(/C=C/C(N=C)=O)c1 YZUIVMCMLUKIBS-VOTSOKGWSA-N 0.000 description 1
- LZPNXAULYJPXEH-AATRIKPKSA-N COc1cccc(/C=C/C(O)=O)c1 Chemical compound COc1cccc(/C=C/C(O)=O)c1 LZPNXAULYJPXEH-AATRIKPKSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/109,395 US8754105B2 (en) | 2005-07-29 | 2011-05-17 | Macrocyclic inhibitors of hepatitis C virus |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05107068 | 2005-07-29 | ||
| EP05107068.8 | 2005-07-29 | ||
| EP05107414.4 | 2005-08-11 | ||
| EP05107414 | 2005-08-11 | ||
| PCT/EP2006/064814 WO2007014920A1 (en) | 2005-07-29 | 2006-07-28 | Macrocyclic inhibitors of hepatitis c virus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20100120855A1 true US20100120855A1 (en) | 2010-05-13 |
Family
ID=37028035
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US11/995,941 Abandoned US20100120855A1 (en) | 2005-07-29 | 2006-07-28 | Macrocylic inhibitors of hepatitis c virus |
| US13/109,395 Expired - Fee Related US8754105B2 (en) | 2005-07-29 | 2011-05-17 | Macrocyclic inhibitors of hepatitis C virus |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US13/109,395 Expired - Fee Related US8754105B2 (en) | 2005-07-29 | 2011-05-17 | Macrocyclic inhibitors of hepatitis C virus |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20100120855A1 (ja) |
| EP (1) | EP1912996B1 (ja) |
| JP (1) | JP5426164B2 (ja) |
| CN (1) | CN101273042B (ja) |
| AR (1) | AR055105A1 (ja) |
| BR (1) | BRPI0614621A2 (ja) |
| DK (1) | DK1912996T3 (ja) |
| ES (1) | ES2389964T3 (ja) |
| MY (1) | MY144895A (ja) |
| RU (1) | RU2441870C2 (ja) |
| TW (1) | TWI383980B (ja) |
| WO (1) | WO2007014920A1 (ja) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8349869B2 (en) | 2005-07-29 | 2013-01-08 | Tibotec Pharmaceuticals Ltd. | Macrocylic inhibitors of hepatitis C virus |
| US8563530B2 (en) | 2010-03-31 | 2013-10-22 | Gilead Pharmassel LLC | Purine nucleoside phosphoramidate |
| US8841275B2 (en) | 2010-11-30 | 2014-09-23 | Gilead Pharmasset Llc | 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| AR048401A1 (es) | 2004-01-30 | 2006-04-26 | Medivir Ab | Inhibidores de la serina-proteasa ns3 del vhc |
| MX2008001402A (es) * | 2005-07-29 | 2008-04-04 | Tibotec Pharm Ltd | Inhibidores macrociclicos del virus de la hepatitis c. |
| TW200745061A (en) * | 2005-07-29 | 2007-12-16 | Tibotec Pharm Ltd | Macrocylic inhibitors of hepatitis C virus |
| PE20070210A1 (es) * | 2005-07-29 | 2007-04-16 | Tibotec Pharm Ltd | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
| TWI375670B (en) * | 2005-07-29 | 2012-11-01 | Tibotec Pharm Ltd | Macrocylic inhibitors of hepatitis c virus |
| PE20070343A1 (es) * | 2005-07-29 | 2007-05-12 | Medivir Ab | Inhibidores macrociclicos del virus de la hepatitis c |
| ATE496042T1 (de) * | 2005-07-29 | 2011-02-15 | Tibotec Pharm Ltd | Makrocyclische inhibitoren des hepatitis-c-virus |
| US7741281B2 (en) | 2005-11-03 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2008008776A2 (en) | 2006-07-11 | 2008-01-17 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| WO2008019289A2 (en) | 2006-08-04 | 2008-02-14 | Enanta Pharmaceuticals, Inc. | Tetrazolyl macrocyclic hepatitis c serine protease inhibitors |
| US8343477B2 (en) | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
| US7772180B2 (en) | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7763584B2 (en) | 2006-11-16 | 2010-07-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8003604B2 (en) | 2006-11-16 | 2011-08-23 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7888464B2 (en) | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| US8383583B2 (en) | 2007-10-26 | 2013-02-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors |
| US8426360B2 (en) * | 2007-11-13 | 2013-04-23 | Enanta Pharmaceuticals, Inc. | Carbocyclic oxime hepatitis C virus serine protease inhibitors |
| WO2009064955A1 (en) | 2007-11-14 | 2009-05-22 | Enanta Pharmaceuticals, Inc. | Macrocyclic tetrazolyl hepatitis c serine protease inhibitors |
| WO2009070692A1 (en) | 2007-11-29 | 2009-06-04 | Enanta Pharmaceuticals, Inc. | C5-substituted, proline-derived, macrocyclic hepatitis c serine protease inhibitors |
| WO2009079353A1 (en) | 2007-12-14 | 2009-06-25 | Enanta Pharmaceuticals, Inc. | Triazole-containing macrocyclic hcv serine protease inhibitors |
| US8283309B2 (en) | 2007-12-20 | 2012-10-09 | Enanta Pharmaceuticals, Inc. | Bridged carbocyclic oxime hepatitis C virus serine protease inhibitors |
| US8202996B2 (en) | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
| CN102015652A (zh) | 2008-03-20 | 2011-04-13 | 益安药业 | 作为丙型肝炎病毒抑制剂的氟化大环化合物 |
| US8163921B2 (en) | 2008-04-16 | 2012-04-24 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP5529120B2 (ja) | 2008-05-29 | 2014-06-25 | ブリストル−マイヤーズ スクイブ カンパニー | Ｃ型肝炎ウイルス阻害剤 |
| US7964560B2 (en) | 2008-05-29 | 2011-06-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
| US8207341B2 (en) | 2008-09-04 | 2012-06-26 | Bristol-Myers Squibb Company | Process or synthesizing substituted isoquinolines |
| US8563505B2 (en) | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8044087B2 (en) | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8283310B2 (en) | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP5793084B2 (ja) | 2008-12-23 | 2015-10-14 | ギリアド ファーマセット エルエルシー | プリンヌクレオシドの合成 |
| CA2748057C (en) | 2008-12-23 | 2018-07-03 | Pharmasset, Inc. | Nucleoside phosphoramidates |
| BRPI0922508A8 (pt) | 2008-12-23 | 2016-01-19 | Pharmasset Inc | Análogos de nucleosídeo |
| CN104856991A (zh) | 2009-02-27 | 2015-08-26 | 西佳技术公司 | 用于治疗和预防登革热病毒感染的噻吩并吡啶衍生物 |
| US8377962B2 (en) | 2009-04-08 | 2013-02-19 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| TWI598358B (zh) | 2009-05-20 | 2017-09-11 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| AR077712A1 (es) | 2009-08-05 | 2011-09-14 | Idenix Pharmaceuticals Inc | Inhibidores de serina proteasa macrociclica |
| PE20130198A1 (es) * | 2010-03-10 | 2013-03-24 | Abbvie Bahamas Ltd | Composiciones solidas |
| JP5872539B2 (ja) | 2010-03-31 | 2016-03-01 | ギリアド ファーマセット エルエルシー | プリンヌクレオシドホスホルアミダート |
| CN102858790A (zh) | 2010-03-31 | 2013-01-02 | 吉利德制药有限责任公司 | 核苷氨基磷酸酯 |
| US8759527B2 (en) | 2010-08-25 | 2014-06-24 | Bayer Cropscience Ag | Heteroarylpiperidine and -piperazine derivatives as fungicides |
| WO2012109398A1 (en) | 2011-02-10 | 2012-08-16 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections |
| US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2012171332A1 (zh) | 2011-06-16 | 2012-12-20 | 爱博新药研发(上海)有限公司 | 抑制丙型肝炎病毒的大环状杂环化合物及其制备和应用 |
| SG10201602044WA (en) | 2011-09-16 | 2016-04-28 | Gilead Pharmassett Llc | Methods For Treating HCV |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| MX360452B (es) | 2012-10-19 | 2018-11-01 | Bristol Myers Squibb Co | Inhibidores del virus de la hepatitis c. |
| US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9598433B2 (en) | 2012-11-02 | 2017-03-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2014071007A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| WO2014070974A1 (en) | 2012-11-05 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| CA2852867C (en) | 2013-01-31 | 2016-12-06 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
| WO2014137869A1 (en) | 2013-03-07 | 2014-09-12 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| MX2016002185A (es) | 2013-08-27 | 2016-06-06 | Gilead Pharmasset Llc | Formulacion combinada de dos compuestos antivirales. |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5484801A (en) * | 1994-01-28 | 1996-01-16 | Abbott Laboratories | Pharmaceutical composition for inhibiting HIV protease |
| US5807876A (en) * | 1996-04-23 | 1998-09-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
| US5948436A (en) * | 1993-09-13 | 1999-09-07 | Abbott Laboratories | Pharmaceutical composition |
| US6037157A (en) * | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
| US6054472A (en) * | 1996-04-23 | 2000-04-25 | Vertex Pharmaceuticals, Incorporated | Inhibitors of IMPDH enzyme |
| US6498178B2 (en) * | 1999-03-19 | 2002-12-24 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
| US20050143316A1 (en) * | 2003-11-20 | 2005-06-30 | Yong Tu | Hepatitis C virus inhibitors |
| US7671032B2 (en) * | 2004-01-30 | 2010-03-02 | Medivir Ab | HCV NS-3 serine protease inhibitors |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0727419T3 (da) | 1992-12-29 | 2002-06-10 | Abbott Lab | Mellemprodukter til fremstilling af forbindelser, som inhiberer retroviral protease |
| US5559158A (en) | 1993-10-01 | 1996-09-24 | Abbott Laboratories | Pharmaceutical composition |
| CN1116288C (zh) | 1996-04-23 | 2003-07-30 | 沃泰克斯药物股份有限公司 | 用作肌苷－5'－一磷酸脱氢酶抑制剂的脲衍生物 |
| JP4080541B2 (ja) | 1996-10-18 | 2008-04-23 | バーテックス ファーマシューティカルズ インコーポレイテッド | セリンプロテアーゼ、特にｃ型肝炎ウイルスｎｓ３プロテアーゼの阻害因子 |
| GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
| DE69816280T2 (de) | 1997-03-14 | 2004-05-27 | Vertex Pharmaceuticals Inc., Cambridge | Inhibitoren des impdh-enzyms |
| EP1012180B1 (en) | 1997-08-11 | 2004-12-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor peptide analogues |
| US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| US6608027B1 (en) | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
| UA74546C2 (en) * | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
| KR100891240B1 (ko) | 2000-08-30 | 2009-04-01 | 파나소닉 주식회사 | 플라즈마 디스플레이 표시장치 및 그 제조방법 |
| NZ561851A (en) * | 2002-04-11 | 2009-05-31 | Vertex Pharma | Inhibitors of serine proteases, particularly hepatitis C virus NS3 - NS4 protease |
| KR100940619B1 (ko) | 2003-02-07 | 2010-02-05 | 이난타 파마슈티칼스, 인코포레이티드 | 마크로사이클릭 씨형 간염 세린 단백효소 억제제 |
| ATE422895T1 (de) * | 2003-04-16 | 2009-03-15 | Bristol Myers Squibb Co | Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus |
| US7125845B2 (en) * | 2003-07-03 | 2006-10-24 | Enanta Pharmaceuticals, Inc. | Aza-peptide macrocyclic hepatitis C serine protease inhibitors |
| DK1680137T3 (da) | 2003-10-14 | 2013-02-18 | Hoffmann La Roche | Makrocyklisk carboxylsyre- og acylsulfonamidforbindelse som inhibitor af HCV-replikation |
-
2006
- 2006-07-28 CN CN2006800354692A patent/CN101273042B/zh not_active Expired - Fee Related
- 2006-07-28 JP JP2008523376A patent/JP5426164B2/ja not_active Expired - Fee Related
- 2006-07-28 DK DK06764265.2T patent/DK1912996T3/da active
- 2006-07-28 BR BRPI0614621-0A patent/BRPI0614621A2/pt not_active IP Right Cessation
- 2006-07-28 ES ES06764265T patent/ES2389964T3/es active Active
- 2006-07-28 EP EP06764265A patent/EP1912996B1/en active Active
- 2006-07-28 US US11/995,941 patent/US20100120855A1/en not_active Abandoned
- 2006-07-28 RU RU2008107738/04A patent/RU2441870C2/ru not_active IP Right Cessation
- 2006-07-28 WO PCT/EP2006/064814 patent/WO2007014920A1/en active Application Filing
- 2006-07-28 AR ARP060103307A patent/AR055105A1/es unknown
- 2006-07-28 TW TW095127589A patent/TWI383980B/zh not_active IP Right Cessation
- 2006-07-28 MY MYPI20063668A patent/MY144895A/en unknown
-
2011
- 2011-05-17 US US13/109,395 patent/US8754105B2/en not_active Expired - Fee Related
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5948436A (en) * | 1993-09-13 | 1999-09-07 | Abbott Laboratories | Pharmaceutical composition |
| US5484801A (en) * | 1994-01-28 | 1996-01-16 | Abbott Laboratories | Pharmaceutical composition for inhibiting HIV protease |
| US6037157A (en) * | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
| US5807876A (en) * | 1996-04-23 | 1998-09-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
| US6054472A (en) * | 1996-04-23 | 2000-04-25 | Vertex Pharmaceuticals, Incorporated | Inhibitors of IMPDH enzyme |
| US6344465B1 (en) * | 1996-04-23 | 2002-02-05 | Vertex Pharmaceuticals, Incorporated | Inhibitors of IMPDH enzyme |
| US6498178B2 (en) * | 1999-03-19 | 2002-12-24 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
| US20050143316A1 (en) * | 2003-11-20 | 2005-06-30 | Yong Tu | Hepatitis C virus inhibitors |
| US7671032B2 (en) * | 2004-01-30 | 2010-03-02 | Medivir Ab | HCV NS-3 serine protease inhibitors |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8349869B2 (en) | 2005-07-29 | 2013-01-08 | Tibotec Pharmaceuticals Ltd. | Macrocylic inhibitors of hepatitis C virus |
| US8741926B2 (en) | 2005-07-29 | 2014-06-03 | Janssen R&D Ireland | Macrocyclic inhibitors of hepatitis C virus |
| US8754106B2 (en) | 2005-07-29 | 2014-06-17 | Janssen R&D Ireland | Macrocyclic inhibitors of hepatitis C virus |
| US9040562B2 (en) | 2005-07-29 | 2015-05-26 | Janssen R&D Ireland | Macrocyclic inhibitors of hepatitis C virus |
| US9353103B2 (en) | 2005-07-29 | 2016-05-31 | Janssen Sciences Ireland Uc | Macrocyclic inhibitors of hepatitis C virus |
| US9623022B2 (en) | 2005-07-29 | 2017-04-18 | Janssen Sciences Ireland Uc | Macrocyclic inhibitors of hepatitis C virus |
| US9856265B2 (en) | 2005-07-29 | 2018-01-02 | Janssen Sciences Ireland Uc | Macrocyclic inhibitors of hepatitis C virus |
| US8563530B2 (en) | 2010-03-31 | 2013-10-22 | Gilead Pharmassel LLC | Purine nucleoside phosphoramidate |
| US8841275B2 (en) | 2010-11-30 | 2014-09-23 | Gilead Pharmasset Llc | 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections |
| US9394331B2 (en) | 2010-11-30 | 2016-07-19 | Gilead Pharmasset Llc | 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1912996A1 (en) | 2008-04-23 |
| US8754105B2 (en) | 2014-06-17 |
| AR055105A1 (es) | 2007-08-08 |
| DK1912996T3 (da) | 2012-09-17 |
| TW200800945A (en) | 2008-01-01 |
| RU2008107738A (ru) | 2009-09-10 |
| CN101273042A (zh) | 2008-09-24 |
| MY144895A (en) | 2011-11-30 |
| JP2009502883A (ja) | 2009-01-29 |
| ES2389964T3 (es) | 2012-11-05 |
| US20110237621A1 (en) | 2011-09-29 |
| CN101273042B (zh) | 2013-11-06 |
| TWI383980B (zh) | 2013-02-01 |
| JP5426164B2 (ja) | 2014-02-26 |
| BRPI0614621A2 (pt) | 2011-04-12 |
| EP1912996B1 (en) | 2012-06-20 |
| RU2441870C2 (ru) | 2012-02-10 |
| WO2007014920A1 (en) | 2007-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8754105B2 (en) | Macrocyclic inhibitors of hepatitis C virus | |
| US9856265B2 (en) | Macrocyclic inhibitors of hepatitis C virus | |
| US8227407B2 (en) | Macrocyclic inhibitors of hepatitis C virus | |
| US7989471B2 (en) | Macrocyclic inhibitors of hepatitis C virus | |
| US8183277B2 (en) | Macrocylic inhibitors of hepatitis C virus | |
| US8012939B2 (en) | Macrocyclic inhibitors of hepatitis C virus | |
| US9023808B2 (en) | Macrocyclic inhibitors of hepatitis C virus | |
| US7666834B2 (en) | Macrocyclic inhibitors of hepatitis C virus | |
| US8937080B2 (en) | Pyrimidine substituted macrocyclic HCV inhibitors | |
| WO2008096002A1 (en) | Hcv inhibiting macrocyclic phosphonates and amidophosphates | |
| MX2008001397A (es) | Inhibidores macrociclicos del virus de la hepatitis c |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
| AS | Assignment |
Owner name: JANSSEN R&D IRELAND, IRELAND Free format text: CHANGE OF NAME;ASSIGNOR:TIBOTEC PHARMACEUTICALS;REEL/FRAME:032092/0094 Effective date: 20120106 Owner name: TIBOTEC BVBA, BELGIUM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SIMMEN, KENNETH ALAN;DE KOCK, HERMAN AUGUSTINUS;RABOISSON, PIERRE JEAN-MARIE BERNARD;AND OTHERS;REEL/FRAME:032091/0483 Effective date: 20060904 Owner name: TIBOTEC PHARMACEUTICALS LTD., IRELAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TIBOTEC BVBA;REEL/FRAME:032091/0917 Effective date: 20080110 Owner name: MEDIVIR AB, SWEDEN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NILSSON, KARL MAGNUS;SAMUELSSON, BENGT BERTIL;ROSENQUIST, ASA ANNICA KRISTINA;AND OTHERS;REEL/FRAME:032091/0098 Effective date: 20060904 |